Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients
- 27 September 2007
- journal article
- research article
- Published by Springer Science and Business Media LLC in European Journal of Clinical Pharmacology
- Vol. 63 (12), 1135-1141
- https://doi.org/10.1007/s00228-007-0381-6
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- A PK–PD Model for Predicting the Impact of Age, CYP2C9, and VKORC1 Genotype on Individualization of Warfarin TherapyClinical Pharmacology & Therapeutics, 2007
- Gamma-glutamyl carboxylase (GGCX) microsatellite and warfarin dosingBlood, 2005
- [The efficiency and safety of anticoagulation therapy in atrial fibrillation in Chinese].2004
- Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarinClinical Pharmacology & Therapeutics, 2004
- Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2Nature, 2004
- Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factorsThe Pharmacogenomics Journal, 2003
- Long-Term, Low-Intensity Warfarin Therapy for the Prevention of Recurrent Venous ThromboembolismThe New England Journal of Medicine, 2003
- A comparison of a low-dose warfarin induction regimen with the modified Fennerty regimen in elderly inpatientsAge and Ageing, 2000
- Multicentre randomised study of computerised anticoagulant dosageThe Lancet, 1998
- Flexible induction dose regimen for warfarin and prediction of maintenance dose.BMJ, 1984